Results 111 to 120 of about 11,226 (207)

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

DARATUMUMAB: REVISÃO DA ATUAÇÃO E INTERFERÊNCIA NOS TESTES PRÉ- TRANSFUSIONAIS EM PACIENTES COM DIAGNOSTICO DE MIELOMA MÚLTIPLO

Hematology, Transfusion and Cell Therapy
Objetivo: Discutir a interferência da medicação Daratumumab nos testes pré-transfusionais em amostras de pacientes diagnosticados com Mieloma Múltiplo que necessitam de transfusões sanguíneas.
GN Leôncio
doaj   +1 more source

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy.
Alexander Carpinteiro, Christoph Kimmich, Despina Trajanova, Ute Hegenbart, Timon Hansen, Udo Holtick, Vera von Landenberg‐Roberg, Stephan Rainer Bohl, Raphael Teipel, Ivana von Metzler, Monika Engelhardt, Evgenii Shumilov, Maximilian Steinhardt, Hans Christian Reinhardt, Sara Oubari, Stefan Schönland   +15 more
wiley   +1 more source

Daratumumab: A Review in Relapsed or Refractory Multiple Myeloma

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no ...
Hannah A. Blair (5008301)
core   +1 more source

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Measurable residual disease assessment in bone marrow (BM‐MRD) is a crucial prognostic factor in multiple myeloma (MM), but its clinical use has some caveats, such as invasiveness, poor spatial representativity, and serial sampling. Novel minimally invasive approaches for monitoring peripheral residual disease (PRD) could facilitate its ...
Natalia Buenache, Marta Lasa, Andrés Arroyo, Carmen González, Larissa Haertle, Yanira Ruiz‐Heredia, Rosa Ayala, Rafael Alonso, Alejandro Martín‐Muñoz, Juan M. Rosa‐Rosa, Verónica González, María J. Calasanz, Paula Rodríguez‐Otero, Laura Rosiñol, Felipe De Arriba, Enrique M. Ocio, Albert Oriol, Yolanda González, Anna Sureda, Sunil Lakhwani, María E. Clavero, Angela Ibáñez, Clara Gómez, Alberto Orfao, María‐Victoria Mateos, Juan J. Lahuerta, María T. Cedena, Joan Bladé, Jesús San Miguel, Noemi Puig, Bruno Paiva, Joaquín Martínez‐López   +31 more
wiley   +1 more source

Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia – Case Report

Ibrahim Zoubi,1 Amir Warwar,1,2 Shoshan Perek,1 Meir Preis1,2 1Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; 2Bruce and Ruth Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, IsraelCorrespondence:
Preis M, Warwar A, Perek S, Zoubi I
core  

Pretransfusion Testing and Daratumumab: Assessing Interference Risks and Developing Solutions

Global Journal of Transfusion Medicine
Daratumumab is a monoclonal antibody; anti-CD38 is used for the treatment of multiple myeloma and other hematological disorders. Daratumumab, binds to CD 38 on red blood cells (RBCs), interfering with pretransfusion testing. This interference can lead to
Saroj Rajput, Tathagata Chatterjee, Rahul Bhargava, Sanjay Rai   +3 more
doaj   +1 more source

Characterizing the Fate of Anti‐CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma

Journal of Extracellular Vesicles, Volume 15, Issue 6, June 2026.
ABSTRACT Extracellular vesicles (EVs) are promising delivery vehicles capable of transporting therapeutic agents across biological barriers. However, native EVs primarily accumulate in liver, spleen and lungs, limiting targeted delivery to disease sites.
Michiel De Coster, Lukas Hyka, Sophie De Cock, Sofie Meeussen, Zuowei Wang, Chenggong Tu, Sophie Hernot, Nick Devoogdt, Guido David, Kim De Veirman, Karin Vanderkerken, Eline Menu, Pascale Zimmermann, Elke De Bruyne   +13 more
wiley   +1 more source

Rapid identification of daratumumab interference with M-protein detection using MALDI-TOF mass spectrometry: a case study involving renal light chain amyloidosis

Practical Laboratory Medicine
Therapeutic monoclonal antibodies (t-mAbs), such as daratumumab (anti-CD38), are increasingly used in plasma cell disorders including systemic AL amyloidosis.
Hou-Long Luo, Anping Xu, Ling Ji
doaj   +1 more source

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline‐recommended triplet or quadruplet therapy in clinical practice. Methods This retrospective cohort study included adult patients newly diagnosed with multiple myeloma between January 1, 2017, and December 31, 2023, in one health system
Emily R. Wesley, Faiz Anwer, Michael B. Rothberg, Jeffrey D. Kovach, Nicholas J. Casacchia, Brittany Peterre, Ming Wang, Shahzad Raza, Louis S. Williams, Jason Valent, Hamlet Gasoyan   +10 more
wiley   +1 more source